Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.
Also called NCT01644474
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 103 participants
- Sponsor
- Registry
-
NCT01644474 -
2011-001424-38
-
- Main results
- Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial
- Other papers using this trial's data
- ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Finland, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT01644474. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2015-11-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
- Acronym
- ODYSSEY MONO
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Placebo (for Alirocumab)
- Intervention (Drug)
- Placebo (for Ezetimibe)
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct01644474- Content hash
224fb9533e05bba90a883cc19fdfa48e7d1473f708f2e0b016644cbeb6e806b9